Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: He's not sure when the second-year starter will be healthy enough to be cleared to play. Allen was placed in the NFL's concussion protocol after taking a helmet-to-helmet hit by Patriots defensive back Jonathan Jones in the opening minute of the fourth quarter of a 16-10 loss to New England on Sunday. Putting aside the three interceptions Allen threw, McDermott's biggest question was why Jones wasn't ejected. "There's no room in football for that," McDermott said. "I thought he should have been thrown out. But other than that, I'm not going to get into that. That's for the league to get into." The hit occurred when Allen scrambled out of the pocket and burst through a hole up the middle while facing third-and-8 at the New England 45. He gained 7 yards before Jones closed in on him, lowered his helmet and struck the quarterback in the crown of his helmet. Jones was flagged for a personal foul for unnecessary roughness. Allen lay on the field for several minutes before hopping up on his own. He was briefly evaluated on the sideline before being escorted up the tunnel. Allen was spotted in the locker room chatting with teammates following the game. NFL officiating chief Al Riveron told a pool reporter the decision to not eject Jones came because the hit did not rise to the level of the league standard for disqualification. "There was a foul called and obviously the penalty stood, but we did not feel this contact rose to that level," Riveron said, who also noted Jones was turning his head just before hitting Allen. Bills safety Micah Hyde questioned the official's judgment saying he or any of his teammates would have been ejected for a similar hit on New England's Tom Brady. "That's our quarterback. We ride or die with him," Hyde said. "To see that happen, Josh didn't slide, but at the end of the day it doesn't matter if you're a running back, you can't head to the head." Jones defended the hit saying it was never his intent to hurt Allen. "No malice or intent. Just a part of football," Jones said. "We're just running around playing football. I hope he's OK. I'm going to check on him." Allen finished going 13 of 28 for 153 yards, and scored on a 1-yard touchdown dive. Allen's uncertain status leaves Buffalo with veteran backup Matt Barkley the only quarterback on the active roster in preparing to play at Tennessee next weekend. Buffalo then enters its bye week. The loss prevented Buffalo (3-1) from getting off to its first 4-0 start since 2008. Though the Bills defense held Brady in check, their offense was busy coughing up the ball at critical moments for the third time in four games. Allen threw three interceptions, two of which translated into a touchdown and a field goal. Punter Corey Bojorquez also had a punt blocked by J.C. Jackson, which led to Matthew Slater returning it 11 yards for a touchdown to put the Patriots up 13-0 in the first quarter. McDermott was unhappy with Allen's continuing string of committing turnovers. He's now thrown six interceptions and lost two fumbles in four starts this season. "He's a young quarterback and sometimes they have to learn those lessons. Those are hard lessons and we have to continue to coach it up," McDermott said. The game was decided on Buffalo's fourth turnover with 1:27 left. Facing third-and-9 on the New England 39, Barkley was pressured by linebacker Kyle Van Noy, who got his hand on the quarterback's chest. That forced Barkley to throw the ball up into the air, and have it easily picked off by Jamie Collins. The loss spoiled a stout effort by a Bills defense which limited the Patriots to just 11 first downs and 224 yards. Brady finished 18 of 39 for 150 yards and an interception. He was picked off by Hyde in the end zone on third-and-goal from the 2 in the second quarter. Brady's 45.9 passer rating was the sixth lowest of his career and lowest since finishing with a 34 rating in a 27-20 loss to Indianapolis on Nov. 5, 2006. Barkley lamented how the Bills let the Patriots off the hook. "Especially with the way our defense played and where we had the ball at the end of the game, it's tough," Barkley said. "This is a tough one." ___ More AP NFL: https://apnews.com/NFL and https://twitter.com/AP_NFL

Answer: Bills fall to Pats, and lose QB Josh Allen to head injury.

Question: Republicans on the GOP-majority Senate Environment and Public Works Committee mostly had praise for Andrew Wheeler, who has served as the agency's acting head since Scott Pruitt's resignation in July amid ethics scandals. The committee chairman, Sen. John Barrasso, R-Wyo., called Wheeler "very well-qualified" to take the job. But Democrats pressed Wheeler about his work as a lobbyist helping an influential coal magnate meet with Trump administration officials before his nomination to the EPA and his moves on deregulation and on what they said was his inattention to the growing dangers of climate change. "You seem to be consistently doing things that undermine the health and safety of this nation," Sen. Ed Markey, D-Mass., told Wheeler. Markey asked him why he was pulling back on regulations that proponents say protect human health and the environment. "I believe we are moving forward" on protections, Wheeler responded. Wheeler cited changes he had initiated to roll back future mileage standards for cars and autos and to ease Obama-era clampdowns on dirtier-burning coal-fired power plants. He said EPA staff, whom he did not identify, had concluded that those rollbacks would ultimately lead to health gains. Environmental groups and formal assessments from the EPA and other agencies have contested that, saying the changes would increase pollution and increase harm to people and the climate. Sen. Tom Carper, D-Del., said the rollbacks in car mileage standards and toxic mercury emissions under Wheeler were examples of unsafe deregulation and went beyond what industries themselves wanted. Sen. Bernie Sanders, I-Vt., noted Wheeler had failed to mention climate change in his initial remarks to lawmakers. "Do you agree that climate change is a global crisis?" Sanders asked, shouting at times. "I would not call it the greatest crisis," Wheeler said. "I would call it a huge issue that has to be addressed globally." Wheeler told lawmakers that he had yet to read a massive government climate change report released late last year that emphasized man-made climate change was already underway. Wheeler said he had received one staff briefing so far on the climate change report. The work of the EPA and other government agencies, the report stresses the massive economic toll expected from increasingly severe wildfires, hurricanes and other extreme weather under climate change. Wheeler said the news media had seized upon "worst-case scenarios" of the climate report. "You are a former coal industry lobbyist that is sitting here," Markey responded. "That's the worst-case scenario, what you are proposing here" for easing Obama-era rules meant to clamp down on climate-changing fossil fuel emissions. Sen. Joni Ernst of Iowa and other Republican lawmakers, by contrast, praised Wheeler for a move to remove federal protections for millions of miles of wetlands and waterways and other proposals. Republican lawmakers said the protections had burdened farmers and others. The grandson of a coal miner, Wheeler worked for the EPA in the 1990s and later as a longtime Republican Senate staffer. Democrats pressed Wheeler about his lobbying before joining the EPA, saying his work for coal companies should disqualify him from leading an agency that regulates coal. Wheeler's lobbying clients included coal magnate Bob Murray, who pushed hard on the Trump administration after the 2016 elections to grant a series of breaks for the sagging domestic coal industry. Wheeler accompanied Murray to a March 2017 meeting to pitch Murray's list of desired rule rollbacks and other breaks for coal to Energy Secretary Rick Perry. Wheeler told senators that his main work for Murray had been on health benefits and pensions. "I did not work on the plan. I do not have a copy of it. I saw it briefly," Wheeler said, referring to Murray's wish list. Sen. Sheldon Whitehouse, D-R.I., displayed a blown-up version of a photo taken of the meeting with Perry, showing Wheeler at Murray's side. A second photo showed Murray's rollback plan in Wheeler's hands. Murray had sought some of the coal breaks that the EPA under Wheeler has since acted on. That included Wheeler signing a rule easing federal regulation of toxic coal ash, redoing an Obama rule that pushed electricity providers to move away from dirtier-burning coal plants and targeting an Obama rule limiting emissions of toxic mercury from coal plants. A watchdog group, Citizens for Responsibility and Ethics in Washington, filed an ethics complaint Tuesday with the EPA's Office of the Inspector General alleging that Wheeler's oversight of those and other rollback proposals at EPA may have violated his government ethics pledge to abstain from regulatory decisions affecting his former lobbying client for at least two years. EPA spokesman John Konkus called the accusation "baseless" and "wrong" and said Wheeler works with EPA ethics officials and follows their guidance.

Answer: Democrats hit Trump EPA nominee on coal lobbying, rollbacks.

Question: "The cost of currently available low-dose, pulsed immune suppressing drugs could have been mentioned. It would be good to know if there would be a potential cost-saving for the patient with HiCy therapy. The story does note the economics driving drug research and implications for the development of new treatments for people with difficult-to-treat chronic conditions. The suggestion that results of this study could lead to a cure for MS seems premature, especially given the small number of people involved and outcomes at 2 years; however, the story does note the limited information available for HiCy and the need for future randomized controlled trials with a larger group of patients. The story mentions the harms of treatment typically seen in patients taking the pulsed dose of cyclophosphamide, as well as side effects seen in the small group of patients in the HiCy trial. These included: nausea and hair loss and increased risk of infection. The story also mentioned that some patients' symptoms became worse before they improved. Researchers do not currently know the long-term effects of this high-dose, concentrated drug regimen. The story adequately describes the small, open-label, pilot-stage study of 9 MS patients and presents findings for the lay reader. The story appropriately notes inclusion criteria for the study (i.e. early stages of aggressive MS) and cautions that the preliminary findings may not apply to other people with different subtypes of MS. The story provides some data on study endpoints, i.e. brain lesions in 7 of 9 people improved and there was a statistically significant reduction in disability in most participants. The story does not engage in disease mongering. The story includes U.S. prevalence data and describes different forms of MS, qualifying discussion of the novel treatment with a reminder that HiCy was only tested in very debilitated patients. As mentioned in the press release accompanying this story, the study included the ""worst of the worst"" MS patients. The story includes interview with study authors and participants, as well as Dr. Richert, VP of research and clinical programs for MS Society, who puts the results of this study in perspective. The story mentions other FDA-approved treatments for MS and compares the current use of longer-term pulsed intervals of cyclophosphamide with the higher-concentrated regimenwhich lasted only 4 days and was less toxic. The story notes that this experimental delivery system was tested in people in the early stages of a particularly aggressive form of MS, and the treatment is not a long-term cure. The story mentions that high-dose cyclophosphamide (generic name for Cytoxan, Neosar, Revimmune) (HiCy) is currently being studied via clinical trials, and at this time the concentrated form of the immunosuppressant drug is limited to people in the early stages of an aggressive form of MS. The story mentions that cyclophosphamide is already used ina different dosing regimen for treatment of MS. The high-dose regimen is under study and more information about risk and efficacy is needed before it can be accepted for clinical use. The story describes the pros and cons of this new method of administering an existing drug to a subset of patients in the early stages of a particularly debilitating form of MS. The story discusses why this method of delivery may be an improvement over existing immunosuppressant drugs regimens for difficult-to-treat cases. There is similar language in the press release and news story; however, there is also some independent reporting and the story includes a perspective (MS researcher Dr. Richert) other than those of the researchers and participants from the HiCy trials."

Answer:
"I've gotten my life back": Hopkins reports success with MS treatment